tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Scl
Transcranial Direct Current Stimulation to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- transcranial direct current stimulation
Results by group
Neuropathic Pain Questionnaire (NPQ) Contains 12 Items.
2 Months
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| tDCS Effects on Pain and Fatigue | 21.3 Points | 19.5 (Standard Deviation) | 6 |
| Sham Effects on Pain and Fatigue | 10.3 Points | 13.5 (Standard Deviation) | 6 |
tDCS Effects on Pain and Fatigue
Sham Effects on Pain and Fatigue
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| tDCS Effects on Pain and Fatigue | 6 | 0 (0.0%) | 0 |
| Sham Effects on Pain and Fatigue | 6 | 0 (0.0%) | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Neuropathic Pain Questionnaire (NPQ) Contains 12 Items.
2 Months
Pain
Other measures (1)
Fatigue Severity Scale (FSS) Contains Nine Statements That Attempt to Explore Severity of Fatigue Symptoms.
2 Months
Fatigue
Who could take part
MS (type not specified) · 18 to 70
Show the full criteria
Inclusion criteria
* Medically diagnosed with Multiple Sclerosis * 18-70 yrs. of age, moderate disability (Patient Determined Disease Steps (PDDS) core 2-6) * Self-reported differences in function between legs * Able to walk for 6 min * Presenting with chronic, drug-resistant, neuropathic pain.
Exclusion criteria
* Relapse within last 60 days * High risk for cardiovascular disease (ACSM risk classification) * Changes in disease modifying medications within last 45 days * Concurrent neurological/neuromuscular disease * Hospitalization within last 90 days * Diagnosed depression * Inability to understand/sign informed consent.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to investigate the effects of transcranial direct current stimulation (tDCS) on neuropathic pain and fatigue in people with MS. The investigators will conduct tDCS or sham on 5 consecutive days. They will evaluate pain and fatigue with specific questionnaires and measure fatigability with an isokinetic device. The research question is whether tDCS can lessen neuropathic pain and increase fatigue resistance in people with MS. It is hypothesized, that less neuropathic pain and increased fatigue resistance after the tDCS sessions.
Loading reviews and guidelines…
History
Started
Apr 2019
Main results due
Mar 2020
Finished
Mar 2020
Results posted
Aug 2022